Evaluation of the Safety and Effectiveness of the Investigational Product in Improvement of the A… (NCT05997654) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of the Safety and Effectiveness of the Investigational Product in Improvement of the Appearance of Wrinkles and General Aspect of the Skin
Brazil33 participantsStarted 2023-05-17
Plain-language summary
The study investigates the safety and effectiveness of SILIMED® brand MEDGEL ANTIAGE with indication for improvement of the appearance of wrinkles and general aspects of the skin.
Who can participate
Age range30 Years – 55 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants aged between 30 and 55 years old;
* Participants with all skin types (normal, dry, combination and oily);
* Participants with mild to moderate signs of aging, according to Lanier's classification;
* Participants with melanic and/or vascular dark circles;
* Participants with bags around their eyes;
* Users of products from the same category;
* Intact skin in the product analysis region (face);
* Participants who agree NOT to use any other topical products on the test area during the study period;
* Agreement to comply with the trial procedures and to attend the clinic on the specified days and times;
* Understand, consent and sign the informed consent.
Exclusion Criteria:
* Participants diagnosed with COVID-19 in the last 4 weeks or showing symptoms such as fever, dry cough, tiredness, body aches or other discomfort;
* Pregnancy/lactation or intention to become pregnant during the study period;
* Use of the following topical or systemic medications: immunosuppressants, antihistamines, non-steroidal anti-inflammatory drugs, and corticoids up to 30 days before selection or considering immunosuppressants, the interval should be 3 months before selection;
* Atopic or allergic history of health products;
* Pathologies and/or active skin lesions (local and/or disseminated) in the assessment area;
* Skin marks in the experimental area that interfere with the evaluation of possible skin reactions (vascular malformations, scars, increased hairiness…